Item 7.01 Regulation FD Disclosure

Story continues below

On August 27, 2019 Lexaria announced that it was advised that it had been granted the following new patent in Australia: #2016367037 / Grant Date August 15, 2019 – “Stable ready-to-drink beverage compositions comprising lipophilic active agents”.

The issuance of this patent has increased Lexaria’s patent portfolio to 16 awarded patents protecting its DehydraTECH™ drug delivery platform, with 8 granted in the USA and 8 granted in Australia.

This new Australian patent, together with Australian Patent #2016367036 “Methods for formulating orally ingestible compositions comprising lipophilic active agents” as announced on August 15, 2019 and as disclosed in the Form 8-K dated August 16, 2019, are the first patents granted in Lexaria’s second and third patent families which differ from the Company’s original patent family, “Food and beverage compositions infused with lipophilic active agents and methods of use thereof” under which 14 of Lexaria’s patents have been granted.

The grant of these two new Australian patents is material due to the fact that these new patent families include claims for the use of DehydraTECH technology with respect to not only food and beverage use, but for the first time also for pharmaceutical applications for:

delivery of cannabinoids as methods of treating certain conditions including, but not limited to, heart disease; neurological diseases such as Alzheimer’s, Parkinson’s, schizophrenia, and human immunodeficiency virus (HIV) dementia; obesity, metabolic disorders, hepatic diseases, diabetes, appetite disorders, cancer via chemotherapy, irritable bowel syndrome (IBS), marijuana abuse, and alcohol, opioid, nicotine or cocaine addiction.

In addition, the claims granted in these two new patent families specify a wide range of delivery formats and a broad range of therapeutically active substances including cannabinoids; nicotine; non-steroidal anti-inflammatory drugs (NSAIDs) such as acetylsalicylic acid, ibuprofen, diclofenac, indomethacin, and piroxicam; and fat-soluble vitamins including Vitamin E.


Lexaria Bioscience Corp., formerly Lexaria Corp., is a food sciences company. The Company is focused on the delivery of cannabinoid compounds procured from legal, agricultural hemp, through gourmet foods based upon its infusion technologies. Its food sciences activities include the development of its nutrient infusion technologies for the production of superfoods, and the production of food products under its two consumer product brands, ViPova and Lexaria Energy. Its technology is developed to aid absorption and bioavailability of various payload molecules, including cannabinoids, such as cannabidiol (CBD) and tetrahydrocannabinol (THC). Its range of flavors to the ViPova family, are available in 8 to 32 bag portions: Decaf English Breakfast, Earl Grey, Herbal Bengal Chai, Herbal Cherry Black Tea, Herbal Masala Chai, Low-Caf Organic Evening Green Tea and ViPova Light. It produces and sells edible consumer products infused with cannabidiol and available for sale in over 50 states.

An ad to help with our costs